Related Experiment Videos
Ganglioneuroblastoma and fetal hydantoin-alcohol syndromes
Pediatrics
|April 1, 1979
Insights
Fetal hydantoin syndrome may increase the risk of neural crest tumors, including ganglioneuroblastoma. Close monitoring of infants exposed to hydantoins is recommended to detect these rare cancers early.
Area of Science:
- Pediatric Oncology
- Neuro-oncology
- Teratology
Background:
- Fetal hydantoin syndrome (FHS) is a condition caused by prenatal exposure to the anticonvulsant medication phenytoin.
- Neural crest tumors are a diverse group of cancers arising from cells that migrate from the neural crest during embryonic development.
Observation:
- A case report details a 35-month-old boy diagnosed with ganglioneuroblastoma.
- This child also presented with both Fetal Hydantoin Syndrome and Fetal Alcohol Syndrome.
Findings:
- The current case, combined with two recent literature reports, strongly suggests a link between Fetal Hydantoin Syndrome and the development of neural crest tumors.
- This association highlights a potential oncogenic risk associated with in utero hydantoin exposure.
Implications:
- Infants diagnosed with Fetal Hydantoin Syndrome require vigilant surveillance for the early detection of neural crest tumors.
- Further research is warranted to elucidate the specific mechanisms underlying this association and to inform preventative strategies.
Abstract:
A ganglioneuroblastoma developed in a 35-month-old boy with both the fetal hydantoin and fetal alcohol syndromes. Our case, plus two recent reports in the literature, would very likely establish the relationship between fetal hydantoin syndrome and the development of neural crest tumors. Infants exposed in utero to hydantoins should be closely observed for the development of these tumors.